<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384578</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-NASH-02</org_study_id>
    <nct_id>NCT01384578</nct_id>
  </id_info>
  <brief_title>Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis</brief_title>
  <official_title>A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      120 patients of biopsy proven NASH will be randomized into two groups. Cases group will
      receive combination of pentoxiphylline and Vitamin E, and control group will receive only
      Vitamin E.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to randomise 120 patients of biopsy proven NASH into cases and control
      groups.

      Baseline investigations:

      Clinical characteristics

        -  Age

        -  Gender

        -  Anthropometry (BMI, waist circumference, waist- hip ratio, triceps skin fold thickness,
           mid arm circumference)

        -  Alcohol intake should be nil

      Laboratory characteristics

        -  Hemogram, INR, KFT

        -  LFT (especially ALT, GGT) , APRI (AST to platelet ratio)

        -  Fasting Lipid Profile

        -  Other possible etiologies of liver disease (viral markers, ferritin, ANA, IgG,
           ceruloplasmin )

        -  HOMA-IR (II)

        -  Serum uric acid levels Liver stiffness

        -  Fibroscan

        -  MR elastography Radiological characteristics

        -  USG abdomen Variceal status by UGI endoscopy Alpha fetoprotein Pro- inflammatory markers

        -  TNF-alpha, IL-6, adiponectin, leptin and osteopontin Liver biopsy and NAS score
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funds
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>histological outcome in the form of improvement or non- progression in hepatocyte injury and fibrosis (NAS score).</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response in form of anthropometry , HOMA-IR, fasting lipid profiles, biochemical response in form of normalization of ALT and AST levels and reduction in uric</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>pentoxiphylline and Vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxiphylline and Vitamin E</intervention_name>
    <description>Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.</description>
    <arm_group_label>pentoxiphylline and Vitamin E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>Patients in control group will receive vitamin E 800 IU/day</description>
    <arm_group_label>Vitamin E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Persistently abnormal ALT &gt;1.2 times upper limit of normal

          -  Histological evidence of NASH/cirrhosis on liver biopsy. ( The minimal criteria for
             diagnosis of NASH included the presence of lobular inflammation and either ballooning
             of cells or perisinusoidal or pericellular fibrosis in Zone 3 of the hepatic acinus)

        Exclusion Criteria:

          -  A known case of Type 2 diabetes mellitus on treatment

          -  Alcohol intake of more than 40gm / week

          -  If they had evidence of cirrhosis with significant portal hypertension

          -  Ongoing total parenteral nutrition/ jejunal-ileal bypass

          -  Other known liver disease (Hepatitis A to E, autoimmune liver disease, Wilson's
             disease, alpha 1 antitrypsin deficiency and hemochromatosis)

          -  Medication like estrogens, amiodarone, MTx, tamoxifen, ATT

          -  Pregnancy or lactation

          -  Hypersensitivity to methylxanthines (e.g., caffeine, theophylline, theobromine )

          -  Recent retinal/cerebral hemorrhage

          -  Acute myocardial infarction or severe cardiac arrhythmias

          -  Impaired renal function

          -  Hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiv Kumar Sarin, MD,DM</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences (ILBS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

